Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Acute myeloid leukemia (AML) patients exhibit diverse molecular and cytogenetic changes with heterogeneous outcomes. The functionally-derived LSC17 gene expression score has demonstrated strong prognostic significance in retrospective analyses of adult and pediatric AML cohorts, where above-median scores are associated with worse outcomes compared to below-median scores in intensively-treated patients. Here we used a laboratory-developed clinically-validated NanoStringbased LSC17 assay to test the prognostic value of the LSC17 score in a prospective multicentre study of 276 newly-diagnosed AML patients. Each patient's score was classified as high or low by comparison to a previously-established reference score. In the entire cohort, a high LSC17 score was associated with poor risk features, including advanced age and unfavorable genetic mutations. In the subset of 190 patients treated intensively, a high LSC17 score was associated with lower remission rates (63% vs 94% after induction, P.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3324/haematol.2025.287777 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.
Haematologica
July 2025
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Division of Medical Oncology and Hematology, Department of Medicine, University Health Network, Toronto, Ontario M5G 2M9, Canada; Department of Medicine, University of Toronto, Toronto, Ontario M5G 1A1. jean.
Acute myeloid leukemia (AML) patients exhibit diverse molecular and cytogenetic changes with heterogeneous outcomes. The functionally-derived LSC17 gene expression score has demonstrated strong prognostic significance in retrospective analyses of adult and pediatric AML cohorts, where above-median scores are associated with worse outcomes compared to below-median scores in intensively-treated patients. Here we used a laboratory-developed clinically-validated NanoStringbased LSC17 assay to test the prognostic value of the LSC17 score in a prospective multicentre study of 276 newly-diagnosed AML patients.
View Article and Find Full Text PDFIntegrative analysis of epigenetic subtypes in acute myeloid Leukemia: A multi-center study combining machine learning for prognostic and therapeutic insights.
PLoS One
May 2025
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Centre for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: Acute Myeloid Leukemia (AML) exhibits significant heterogeneity in clinical outcomes, yet current prognostic stratification systems based on genetic alterations alone cannot fully capture this complexity. This study aimed to develop an integrated epigenetic-based classification system and evaluate its prognostic value.
Methods: We performed multi-omics analysis on five independent cohorts totaling 1,103 AML patients.
Genetic deletion of JAM-C in preleukemic cells rewires leukemic stem cell gene expression program in AML.
Blood Adv
September 2024
Aix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Equipe Labellisée Ligue 2020, Marseille, France.
Article Synopsis
- The LSC-17 score, based on a gene expression profile related to stemness, indicates poor outcomes in acute myeloid leukemia (AML), but how leukemic stem cell anchoring affects disease progression is unclear.
- Conditional inactivation of the adhesion molecule JAM-C in a mouse model of AML showed that its deletion affected HSC expansion but not disease initiation or progression, revealing insights into leukemic cell behavior in the bone marrow niche.
- Findings suggest that the AP-1/TNF-α gene signature, which correlated with different prognosis in AML, provides additional prognostic information alongside the LSC-17 score, highlighting the importance of niche interactions in leukemia.
Cellular abundance-based prognostic model associated with deregulated gene expression of leukemic stem cells in acute myeloid leukemia.
Front Cell Dev Biol
March 2024
Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Previous studies have reported that genes highly expressed in leukemic stem cells (LSC) may dictate the survival probability of patients and expression-based cellular deconvolution may be informative in forecasting prognosis. However, whether the prognosis of acute myeloid leukemia (AML) can be predicted using gene expression and deconvoluted cellular abundances is debatable. Nine different cell-type abundances of a training set composed of the AML samples of 422 patients, were used to build a model for predicting prognosis by least absolute shrinkage and selection operator Cox regression.
View Article and Find Full Text PDFIntegration of Transcriptomic Features to Improve Prognosis Prediction of Pediatric Acute Myeloid Leukemia With KMT2A Rearrangement.
Hemasphere
December 2023
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Lysine methyltransferase 2A-rearranged acute myeloid leukemia (-r AML) is a special entity in the 2022 World Health Organization classification of myeloid neoplasms, characterized by high relapse rate and adverse outcomes. Current risk stratification was established on the treatment response and translocation partner of . To study the transcriptomic feature and refine the current stratification of pediatric -r AML, we analyzed clinical and RNA sequencing data of 351 patients.
View Article and Find Full Text PDF